Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer

HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer Purpose of Review HER2 activating mutations are a new, druggable mutation identified by next-generation DNA sequencing (NGS) of breast cancer. Here, we review the recent data on the diagnosis and treatment of HER2 mutated, metastatic breast cancer. Recent Findings Pre-clinical studies have shown that HER2 activating mutations accelerate tumor growth and can be inhibited by HER2 targeted drugs, including trastuzumab and the second-generation, pan-HER tyrosine kinase inhibitor, neratinib. HER2 mutations can be diagnosed by NGS testing on either a tumor biopsy or circulating tumor DNA obtained from peripheral blood. Case reports provided initial evidence that HER2 targeted therapies can effectively treat patients with HER2 mutated, metastatic breast cancer. Two phase II clinical trials, MutHER and SUMMIT, both demonstrate that neratinib monotherapy has clinical efficacy for these patients, with clinical benefit rate of 31–40%. Summary HER2 targeted therapies are effective for HER2 mutated breast cancer but emergence of drug resistance remains a problem. Clinical trials are now testing neratinib-containing drug combination regimens for HER2 mutated, metastatic breast cancer patients. . . . . Keywords HER2 mutations Hormone receptor positive breast cancer Cancer genomics Next-generation sequencing Circulating tumor DNA Neratinib Introduction FDA-approved for breast cancer treatment, with the most re- cent http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/her2-activating-mutations-in-estrogen-receptor-positive-breast-cancer-JdYAd4IrJH

References (33)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-018-0265-z
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review HER2 activating mutations are a new, druggable mutation identified by next-generation DNA sequencing (NGS) of breast cancer. Here, we review the recent data on the diagnosis and treatment of HER2 mutated, metastatic breast cancer. Recent Findings Pre-clinical studies have shown that HER2 activating mutations accelerate tumor growth and can be inhibited by HER2 targeted drugs, including trastuzumab and the second-generation, pan-HER tyrosine kinase inhibitor, neratinib. HER2 mutations can be diagnosed by NGS testing on either a tumor biopsy or circulating tumor DNA obtained from peripheral blood. Case reports provided initial evidence that HER2 targeted therapies can effectively treat patients with HER2 mutated, metastatic breast cancer. Two phase II clinical trials, MutHER and SUMMIT, both demonstrate that neratinib monotherapy has clinical efficacy for these patients, with clinical benefit rate of 31–40%. Summary HER2 targeted therapies are effective for HER2 mutated breast cancer but emergence of drug resistance remains a problem. Clinical trials are now testing neratinib-containing drug combination regimens for HER2 mutated, metastatic breast cancer patients. . . . . Keywords HER2 mutations Hormone receptor positive breast cancer Cancer genomics Next-generation sequencing Circulating tumor DNA Neratinib Introduction FDA-approved for breast cancer treatment, with the most re- cent

Journal

Current Breast Cancer Reports – Springer Journals

Published: Apr 20, 2018

There are no references for this article.